Why the study?
Do renin-angiotensin system inhibitors and ACE I/D gene polymorphisms alter the risk of colorectal, lung, breast, and prostate cancer in a general population cohort?
Do renin-angiotensin system inhibitors and ACE I/D gene polymorphisms alter the risk of colorectal, lung, breast, and prostate cancer in a general population cohort?
Renin-angiotensin system inhibitors may protect against cancer in individuals with the ACE DD genotype, despite this genotype being associated with an increased risk of breast cancer.
No takes yet. Share an insight, caveat, or question.
DD genotype may link to higher breast cancer risk modifiable by RAS inhibitors; hypothesis-generating in one cohort and needs prospective validation.
Knaap et al. (2008) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: